These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063 [TBL] [Abstract][Full Text] [Related]
3. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma. El-Hadaad HA; Wahba HA; Roshdy S J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548 [TBL] [Abstract][Full Text] [Related]
5. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335 [TBL] [Abstract][Full Text] [Related]
6. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148 [TBL] [Abstract][Full Text] [Related]
7. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858 [TBL] [Abstract][Full Text] [Related]
8. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909 [TBL] [Abstract][Full Text] [Related]
9. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. Song B; Cui H; Li Y; Cheng C; Yang B; Wang F; Kong P; Li H; Zhang L; Jia Z; Bi Y; Wang J; Zhou Y; Liu J; Wang J; Zhao Z; Zhang Y; Hu X; Shi R; Yang J; Liu H; Yan T; Li Y; Xu E; Qian Y; Xi Y; Guo S; Chen Y; Wang J; Li G; Liang J; Jia J; Chen X; Guo J; Wang T; Zhang Y; Li Q; Wang C; Cheng X; Zhan Q; Cui Y Oncotarget; 2016 Jan; 7(3):3599-613. PubMed ID: 26528858 [TBL] [Abstract][Full Text] [Related]
10. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775 [TBL] [Abstract][Full Text] [Related]
11. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735 [TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status. Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764 [TBL] [Abstract][Full Text] [Related]
14. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Gerard JP; Ayzac L; Hun D; Romestaing P; Coquard R; Ardiet JM; Mornex F Radiother Oncol; 1998 Mar; 46(3):249-56. PubMed ID: 9572617 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Khater R; Frenay M; Bourry J; Milano G; Namer M Cancer Treat Rep; 1986 Nov; 70(11):1345-6. PubMed ID: 3768879 [No Abstract] [Full Text] [Related]
17. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA; Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666 [TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma]. Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688 [TBL] [Abstract][Full Text] [Related]
19. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Graf R; Wust P; Hildebrandt B; Gögler H; Ullrich R; Herrmann R; Riess H; Felix R Oncology; 2003; 65(1):14-22. PubMed ID: 12837978 [TBL] [Abstract][Full Text] [Related]
20. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]